TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pediatric Open-Label Extension Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent from parent(s) or legal guardian(s) with sufficient intellectual capacity to understand the study and support subjects' participation in the study procedures must be obtained for subjects who are not emancipated. In accordance with Institutional Review Board (IRB) or Independent Ethics Committee (IEC) requirements, the subject will complete an informed assent when developmentally appropriate, to participate in the study before conduct of any study-specific procedures.~* Subject has completed Study D1050301 (Visit 9) OR~* Subject has completed Study D1050325 (Visit 9) OR~* Subject has completed Study D1050326 (Visit 8)~* Subject is judged by the investigator to be appropriate for participation in a 104-week clinical trial in an outpatient setting involving open-label lurasidone treatment, and is able to comply with the protocol.~* A reliable informant (eg, parent, legal guardian, or caregiver) must be available to accompany the subject at each visit. For subjects entering from Study D1050325, the reliable caregiver must also oversee the administration of the study drug throughout the study~* Females who participate in this study:~  * are unable to become pregnant (eg, premenarchal, surgically sterile, etc.) -OR-~ * practices true abstinence (consistent with lifestyle) and must agree to remain abstinent from signing informed consent to at least 7 days after the last dose of study drug has been taken; -OR-~ * are sexually active and willing to use a medically effective method of birth control (eg, male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 7 days after the last dose of study drug has been taken.~* Males must be willing to remain sexually abstinent (consistent with lifestyle) or use an effective method of birth control (eg, male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 7 days after the last dose of study drug has been taken.~Exclusion Criteria:~* Subject is considered by the investigator to be at imminent risk of suicide.~* Exhibits evidence of moderate or severe extrapyramidal symptoms, dystonia, tardive dyskinesia, or any other moderate or severe movement disorder. Severity to be determined by the investigator.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Lurasidone 20, 40, 60, 80 mg, flexibly dosed (Type: EXPERIMENTAL): Lurasidone 20, 40, 60, 80 mg, flexibly dosed, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Satisfactorily completion of HMR1726D/2001 study with respect to safety.~* If female subject, non-childbearing potential or child bearing potential with adequate contraception.~* Consent to practice/maintain adequate means of contraception throughout the study and for 24 months after the discontinuation of treatment.~* Clinically definite Multiple Sclerosis (MS) as established on entry into HMR1726D/2001 study.~* Extended Disability Status Score(EDSS) between 0 and 6 inclusively, when the subject entered HMR1726D/2001 study.~* Magnetic Resonance Imaging (MRI) criteria must continue to support the diagnosis of clinically definite MS.~* Willingness to participate in a long-term safety and efficacy trial.~Exclusion Criteria:~* Subject who did not complete HMR 1726D/2001 study for safety reasons.~* Subject who developed clinically relevant cardiovascular, hepatic, endocrine or other major disease.~* Pregnancy.~* Breast-feeding.~* Wish to parent.~* Likelihood of requiring treatment during the study period with drugs not permitted.~* Disallowed therapies such asw immunomodulators, immunosuppressants.~* Recent history of drug or alcohol abuse.~* Liver function impairment.~* Abnormal mental conditions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Teriflunomide 7 mg (Type: EXPERIMENTAL): None
- Teriflunomide 14 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females must be post-menopausal for at least 2 years or surgically sterile or practicing specific forms of birth control.~* Chronic hepatitis C, genotype 1 infection and HCV RNA level greater than 10,000 IU/mL at screening.~* Previous treatment failure of peg-interferon and ribavirin (pegIFN and RBV).~* No evidence of liver cirrhosis.~Exclusion Criteria:~* Positive screen for drugs or alcohol.~* Significant sensitivity to any drug.~* Use of contraindicated medications within 2 weeks of dosing.~* Certain predefined abnormal laboratory tests.~* Positive hepatitis B surface antigen or anti-human immunodeficiency virus antibody.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ABT-450/r/ABT-267 and ABT-333, plus RBV (Type: EXPERIMENTAL): Double-blind ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
- Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV (Type: EXPERIMENTAL): Double-blind placebo for 12 weeks, followed by open-label ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients 18-50 years old~* grass pollen rhinoconjunctivitis of at least 2 years.~* positive specific skin prick test and a specific IgE dosage level of at least 0.70 kU/L at screening.~* written consent~* a positive response to the baseline challenge test (RTSS reaches 7 at one time-point at least during baseline challenge)~Exclusion Criteria:~* Allergic rhino-conjunctivitis due to a co-sensitisation, likely to significantly change the symptoms of the subject throughout the study~* Asthma requiring treatment other than short-acting beta-2 inhaled agonists.~* Desensitisation treatment for grass pollen in the previous five years and current immunotherapy with another allergen.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 300 IR (Type: EXPERIMENTAL): 300 IR grass pollen allergen extract tablet
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Comparison of the Airway Devices

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. The subjects will be adult surgical candidates aged 18-80, ASA I-III, Mallampati I or II, presenting for elective surgery who require general anesthesia in whom tracheal intubation is not necessary.~2. Both male and female patients will be included.~Exclusion Criteria:~* Patients will be excluded from the study if they present as Mallampati III or IV, ASA IV-V or emergency status. Additionally, they will be excluded if they meet one of the contraindication criteria of the LMA ProSeal including:~  1. Obesity~ 2. Pregnancy~ 3. History of gastric regurgitation, heart burn, ileus or full stomach~ 4. History of low pulmonary compliance or high pulmonary resistance~ 5. Known history of difficult endotracheal intubation or signs suggesting the possibility of difficult intubation~ 6. Pharyngeal pathology or~ 7. Upper airway obstruction due to laryngeal pathology.~* Additionally, they will be excluded if they meet one of the contraindication criteria for the Combitube including:~  1. Intact gag reflexes~ 2. Height \<4 feet~ 3. Central airway obstruction~ 4. Recent ingestion of caustic substances~ 5. Known esophageal pathology, or~ 6. Known latex allergy.~* They will also be excluded if any tracheal disease is present such as tracheal tumors, stenosis or previous tracheal surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- LTS-D (Type: EXPERIMENTAL): All the cases were divided into one of the group LTS-D, PLMA, and ETC
- ProSeal Laryngeal Mask Airway (Type: EXPERIMENTAL): All patients were divided into either LTS-D, PLMA, or the ETC group.
- Esophageal Tracheal Combitube (ETC) (Type: EXPERIMENTAL): All patients are divided into one of the group, LTS-D, PLMA, or the ETC.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/ Postoperative Ileus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject is scheduled for a partial small/large bowel resection with primary anastomosis or total abdominal hysterectomy (simple or radical) via laparotomy~* Subject is scheduled to receive primary postoperative pain management with intravenous (i.v.) patient-controlled analgesia (PCA) opioids~Exclusion Criteria:~* Subject is scheduled for a total colectomy, colostomy, ileostomy~* Subject has complete bowel obstruction~* Subject has recently been on an acute course (1-10 days) of opioid analgesics and has not been off all opioids for at least 1 week prior to surgery Subject has been on chronic (\>10 days) opioid analgesics and has not been off all opioids for at least 2 weeks prior to surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA~* The study population will comprise individuals who have transfusion-dependent hemolytic PNH.~* Each patient must meet the following criteria to be enrolled in this study:~  1. Individuals at least 18 years of age~ 2. Patients with a diagnosis of PNH greater than 6 months~ 3. Presence of a GPI deficient red blood cell clone (type III cells) by flow cytometry of greater than or equal to 10%~ 4. Patients must have: at least one transfusion in the past two years for anemia or anemia-related symptoms -or personal beliefs that preclude the use of transfusion, with severe hemolytic PNH~ 5. Documented LDH level greater than or equal to 1.5 x upper limit of normal (ULN) within 12 weeks of Visit 1 or during the Screening Period~ 6. Patient must be willing and able to give written informed consent.~ 7. Patients must avoid conception during the trial using a method that is most appropriate for their physical state and culture.~* Subjects must have a Visa allowing stay in United States for the duration of the study (up to 3 years).~* Subjects must provide documentation of residence during stay in the United States.~* The subject must be willing to keep all visits and not travel outside of the country while being treated under the protocol.~* The subject must understand that the drug may not be made commercially available in their country.~* Once the protocol and extension study is complete, the subject must come off study medication and it will not be made available to them if they return to their country.~EXCLUSION CRITERIA~-Any patient meeting any of the following criteria will be excluded from the study:~1. Platelet count of less than 30,000/mm3~2. Absolute Neutrophil count less than or equal to 500/uL~3. Presence or suspicion of active bacterial infection, in the opinion of the Investigator, at Visit 2 or recurrent bacterial infections~4. Known or suspected hereditary complement deficiency~5. History of bone marrow transplantation~6. Participation in any other investigational drug trial or exposure to other investigational agent, device, or procedure within 30 days prior to screening~7. Pregnant, breast-feeding, or intending to conceive during the course of the study,including the Safety Follow-up Visits~8 .History of meningococcal disease~9. Patients who are not vaccinated against N. meningitidis at least 14 days prior to Visit 2~10. Any condition that, in the opinion of the Investigator, could increase the patient's risk by participating in the study or confound the outcome of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine For Suicidal Ideation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English speaking Male or female patients, 18-80 years~* Patients have voluntarily admitted themselves to an inpatient psychiatric unit at MSH or, regarding the outpatient population, have clinically significant suicidal ideation without intent to harm themselves~* Women of childbearing potential must have a negative pregnancy test~* Clinically significant suicidal ideation and score of ≥4 on MADRS item 10 for suicidality~* Each subject must have a level of understanding sufficient to agree to all tests and examinations required by the protocol and must sign an informed consent document~Exclusion Criteria:~* Lifetime history of schizophrenia or other primary psychotic disorder~* Current presence of psychotic symptoms~* Lifetime history of a clearly established psychotic episode~* Established diagnosis of Schizoid, Schizotypal or Paranoid personality disorder~* Urine toxicology screen positive for drugs of abuse on admission~* Substance abuse or dependence within the preceding 1 month~* Anticipated discharge within 7 days of study enrollment (for patients in the inpatient arm)~* Women who plan to become pregnant, are pregnant or are breast-feeding~* Concurrent course of electroconvulsive therapy (ECT)~* Any unstable medical illness including hepatic, renal, gastro-enterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease~* Clinically significant abnormal findings of laboratory parameters, physical examination, or ECG~* The presence of any known or suspected contraindications to midazolam or ketamine including, but not limited to, known allergic reactions to these agents or acute intermittent porphyria~* Uncontrolled hypertension, defined as BP systolic \>160 or BP diastolic \>100 on medications~* Arrhythmia requiring medication~* Severe coronary artery disease, defined as Canadian Cardiovascular Status III or IV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): single dose IV ketamine, .5mg/kg
- Midazolam (Type: PLACEBO_COMPARATOR): single dose IV midazolam, .45mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Furosemide on Confirmation of Ureteral Patency During Routine Cystoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Undergoing any urogynecologic surgery~* No allergy or contraindication to receiving furosemide~* Normal Creatinine/glomerular filtration rate~Exclusion Criteria:~* Unable to consent, including if non English speaking~* Allergy or contraindication to receiving furosemide~* Intraoperative injury to the lower urinary tract

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- furosemide (Type: EXPERIMENTAL): furosemide 10mg (1mL) IV push for one dose
- placebo (Type: PLACEBO_COMPARATOR): normal saline 1mL IV push for one dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Any patient of any age \[age category: pediatric-newborn infants (0 to 27 days), infants and toddlers (28 days to 23 months), children (2 to 11-years), and adolescents (12 to \<17-years); adult (17-64-years); and geriatric (≥65-years)\] with a confirmed or suspected exposure to botulinum toxin who were treated with BAT® provided by the CDC.~Exclusion Criteria:~* None.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants treated with BAT® (Type: None): Any patient of any age with a confirmed or suspected exposure to botulinum toxin who were treated with BAT®.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Japanese participant diagnosed with compensated CHC GT 1~* Absence of ascites, bleeding esophageal varices, hepatic encephalopathy, or other signs or symptoms of advanced liver disease~* Has received and tolerated treatment with IFN-based therapy (IFN α, IFN β, or peg-IFN) with or without use of ribavirin, but failed to respond to the prior treatment (partial responder or null responder)~* No evidence of cirrhosis~Exclusion criteria:~* Co-infection with human immunodeficiency virus (HIV)~* Positive hepatitis B surface antigen or other evidence of active hepatitis B infection~* Any other condition that is contraindicated or for which caution is required for treatment with peg-IFN or RBV~* Any condition or pre-study laboratory abnormality, or history of any illness, that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering the study drugs, peg-IFN and RBV, to the participant

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Vaniprevir 24 Week Arm (Type: EXPERIMENTAL): Participants receive 24 weeks of vaniprevir (300 mg twice daily) with concomitant peg-IFN and RBV treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
General Inclusion Criteria:~* Patient has type 2 diabetes mellitus (T2DM)~* Patient is inadequately controlled and not on treatment with insulin or oral antihyperglycemic therapy~General Exclusion Criteria:~* Patient has a history of type 1 diabetes mellitus or history of ketoacidosis~* Patient was on antihyperglycemic therapy (insulin or oral) within the prior 4 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Drug
- 2 (Type: ACTIVE_COMPARATOR): Active comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete